Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinforces potential for tividenofusp alfa (DNL310) to address full disease spectrum Launch readiness ...
Open Text Corporation , , today announced its financial results for the second quarter ended December 31, 2025. "We had an ...
Early managed care prioritized coordinated primary care “gatekeeping,” selective contracting, utilization/quality controls, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results